A liquidation trust for Insys Therapeutics Inc. reached a $175 million settlement with the opioid manufacturer’s former board of directors.

The trust, in a draft complaint, alleged that the board of directors failed in their oversight of Insys executives, who engaged in off-label marketing of its fentanyl spray, called Subsys, and paid bribes and kickbacks to doctors.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]